RxDoctor Payments Data

Christine Mason, NP

Family · Republic, MONPI 1821700733

Payments from drug & device makers

$3,120in general payments, 2019–2025

Across 162 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$640
  • Novo Nordisk$490
  • AbbVie$315
  • Lilly USA, LLC$277
  • Pfizer$255
  • Otsuka America Pharmaceutical, Inc.$253
  • plus $890 from 15 others

What the payments were for

  • Food & beverage$3,09399%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,120 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$25,895
Medicare patients
118
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$20,675
EliquisApixaban18$17,909
XareltoRivaroxaban14$10,784
Spiriva HandihalerTiotropium Bromide17$8,511
ProgesteroneProgesterone, Micronized78$3,133
Liothyronine Sodium103$2,448
Armour ThyroidThyroid,pork24$2,248
Gabapentin39$1,107
Np ThyroidThyroid,pork12$855
Sucralfate13$803
Oxybutynin Chloride ErOxybutynin Chloride17$790
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$660
Albuterol Sulfate HfaAlbuterol Sulfate22$546
Estradiol60$500
Verapamil SrVerapamil Hcl11$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$277$20,67521 claims
PfizerEliquis$255$17,90918 claims
AbbVieArmour Thyroid$315$2,24824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.

Other family in Republic

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →